FOXO4-DRI 10mg

Advanced Senolytic & Cellular-Ageing Research Peptide

FOXO4-DRI, also known as proxofim, is a synthetic cell-penetrating peptide widely studied for its senolytic properties and interaction with cellular-ageing pathways.

Researchers investigating longevity, senescence biology, tissue ageing, and cellular-damage pathways are particularly interested in FOXO4-DRI because of its apparent ability to selectively target senescent cells — often referred to in research as “zombie cells.”

Unlike healthy cells that continue functioning normally, senescent cells remain metabolically active while contributing to inflammatory signalling, tissue dysfunction, and age-related biological decline.

FOXO4-DRI has become one of the most recognised investigational compounds within senolytic and healthy-ageing research.

Top Shelf Peptides supplies high-purity FOXO4-DRI 10mg research compounds within Australia with fast domestic dispatch and batch-verified analytical testing.

Supplied as a lyophilised (freeze-dried) powder, FOXO4-DRI is intended strictly for laboratory and in-vitro research purposes only.

What Makes FOXO4-DRI Unique?

FOXO4-DRI is specifically designed to interfere with the interaction between:

• FOXO4 proteins

• p53 signalling pathways

Researchers investigate this interaction because senescent cells often rely on FOXO4-mediated signalling to avoid programmed cellular death.

By disrupting this interaction, researchers study whether FOXO4-DRI may selectively induce apoptosis in senescent cells while leaving healthy non-senescent cells relatively unaffected.

This mechanism has positioned FOXO4-DRI as a major area of interest in senolytic and longevity-focused research.

How FOXO4-DRI Is Commonly Studied

Senolytic Research

One of the primary focuses of FOXO4-DRI research involves:

Cellular Senescence

Researchers investigate whether FOXO4-DRI may influence:

• Senescent-cell clearance pathways

• Cellular-ageing signalling

• Tissue-degeneration models

• Senescence-associated inflammatory pathways

• Cellular-resilience mechanisms

Its apparent selectivity toward senescent-cell populations has generated significant scientific interest.

FOXO4-p53 Interaction Research

FOXO4-DRI is specifically studied for its interaction with:

• FOXO4 transcription-factor pathways

• p53 tumour-suppressor signalling

• Apoptosis regulation

• Cellular survival mechanisms

Researchers investigate whether disrupting FOXO4-p53 binding may redirect p53 activity toward mitochondrial apoptotic pathways.

This mechanism is central to FOXO4-DRI senolytic research.

Longevity & Healthy-Ageing Research

Researchers continue investigating FOXO4-DRI within broader longevity-focused studies involving:

• Age-related tissue decline

• Cellular-resilience pathways

• Inflammatory ageing processes

• Biological-age signalling

• Healthy-ageing models

• Tissue-regeneration research

Senolytic compounds have become an increasingly important area within modern longevity science.

Chemotherapy & Cellular-Stress Research

FOXO4-DRI has additionally been studied in experimental models involving:

• Chemotherapy-induced senescence

• Cellular-damage accumulation

• Tissue-stress pathways

• Recovery-related signalling

• Cellular-survival responses

Researchers continue exploring how senescent-cell accumulation may contribute to broader tissue dysfunction.

Cell-Penetrating Peptide Research

FOXO4-DRI is classified as a:

Cell-Penetrating Peptide

meaning researchers investigate its apparent ability to cross cellular membranes and interact directly with intracellular signalling systems.

This property is considered essential to its senolytic activity.

Research Integrity & Safety Context

FOXO4-DRI remains an investigational senolytic compound and is not approved for therapeutic or clinical human use.

Researchers continue evaluating:

• Off-target pathway activity

• Cellular-selectivity mechanisms

• Long-term senolytic signalling

• Tissue-response pathways

• Senescence-related biological interactions

Because senolytic compounds influence highly complex cellular systems, analytical verification and responsible laboratory handling remain critically important.

Regulatory & Research Status

FOXO4-DRI is widely supplied globally as:

• Research-only material

• Investigational biochemical reagent

• Experimental senolytic compound

It has not received approval from agencies including:

• U.S. Food and Drug Administration

• Therapeutic Goods Administration

for therapeutic human use.

Researchers continue investigating FOXO4-DRI within:

• Longevity science

• Senescence biology

• Cellular-ageing research

• Experimental regenerative studies

Product Information

All products supplied by Top Shelf Peptides are sourced, tested, and dispatched entirely within Australia with fast domestic shipping and batch-specific Certificate of Analysis (CoA) verification available through the CoA Library or by scanning the QR code supplied with each product.

⚠ For laboratory and in-vitro research purposes only. Not for human consumption.

⚠ None of the products supplied by Top Shelf Peptides are approved therapeutic goods unless expressly stated otherwise.

⚠ By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.